Physician profile
Susan E Henley
NPI 1083683049
$8,700.08
in general payments reported to CMS, 2019-2025
32 companies · $630 in 2025
The $630 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,055 · 2020: $2,408 · 2021: $1,960 · 2022: $606 · 2023: $1,018 · 2024: $1,022 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,670.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,462.18 | 2019-2025 | |
| Medtronic, INC. | $1,321.56 | 2021-2025 | Minimed 780g, Minimed 770g |
| Lilly USA, LLC | $577.01 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Medtronic Minimed, INC. | $496.14 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.10 | 2019-2025 | Synjardy, Tradjenta, Jardiance |
| Novo Nordisk INC | $407.97 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $237.96 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $234.90 | 2019-2023 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $203.39 | 2019-2020 | |
| Dexcom, INC. | $182.43 | 2019-2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $178.45 | 2019-2025 | Licart, Flector, Tirosint |
| Ascendis Pharma Endocrinology INC | $117.38 | 2023-2025 | Yorvipath |
| Mannkind Corporation | $85.90 | 2023-2024 | Afrezza |
| Merck Sharp & Dohme LLC | $79.95 | 2019-2020 | |
| Insulet Corporation | $79.53 | 2019-2024 | Omnipod |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $77.77 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $61.38 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $58.81 | 2023-2025 | Strensiq |
| Kyowa Kirin, INC. | $57.04 | 2024-2025 | Crysvita |
| Corcept Therapeutics | $53.57 | 2019-2025 | Korlym |
| Pfizer INC. | $36.57 | 2024 | |
| Nevro Corp. | $30.34 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.83 | 2024 | |
| Sequel Med Tech, LLC | $24.74 | 2025 | Twiist |
| Shire North American Group INC | $23.36 | 2019 | |
| Lifescan, INC. | $20.16 | 2020 | |
| Xeris Pharmaceuticals, INC. | $18.94 | 2025 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $17.60 | 2025 | |
| Cequr Corporation | $15.07 | 2024 | Cequr Simplicity |
| Ultragenyx Pharmaceutical INC. | $14.19 | 2020 | |
| Soleno Therapeutics, INC. | $13.49 | 2025 | Vykat Xr |
| Valeritas, INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Henley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.